As cancer treatments become more effective, we must ask: what is life like for the people who receive them? | Ranjana Srivastava
Recently, researchers at the European Society For Medical Oncology presented the latest chapter results from a randomised controlled trial of a bespoke cancer vaccine for patients with high-risk melanoma.
Key points
- They received either pembrolizumab, an established immunotherapy, or pembrolizumab combined with an experimental mRNA vaccine, designed to help the immune system recognise and attack targets unique to the patient’s tumour.….
- The trial involved 1,137 patients whose melanoma had been surgically removed but remained at high recurrence risk.
- But today, for such patients, there are options that were unimaginable back then.
Many treatments are now extending lives but the measure of progress should not end with a scan or a survival curve Two decades ago, a dear friend called me in a trembling voice.
Was there hope for his young nephew, whose cancer had spread to the brain?
How this summary was made: extractive summary — built from the sources' own reporting. It is drawn only from the reporting of the sources listed below — read the originals for full detail. How we summarize →
Advertisement
Every article behind this summary — 1 article from 1 outlet
Get stories like this in your inbox.
Subscribe — it's freeOne free email at 6am — your topics, deduplicated, five minutes. No account, no paywall.